Pafolacianine Sodium
FDA-approved product (solution, intravenous), marketed as Cytalux.
- Registered studies
- 1
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLNo approved indication recorded
ChEMBL records no approved indication for Pafolacianine Sodium. Its therapeutic class is shown instead.
- WHO therapeutic group
- Other diagnostic agents
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA63.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli61.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae47.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis65.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
1registered study names this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Pafolacianine Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Enalapril MaleateExisting use: Cardiovascular disease, Congestive heart failure, Heart failure and 2 more69.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ElbasvirExisting use: Chronic hepatitis C virus infection, Viral disease69.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- BendroflumethiazideExisting use: Cardiovascular disease, Hypertension68.8% AI-predicted activityagainst M. tuberculosis9 registered studies
- ChlorthalidoneExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 6 more68.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- ChlorothiazideExisting use: Cardiovascular disease, Chronic kidney disease, Congestive heart failure and 6 more68.7% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HaloperidolExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more68.4% AI-predicted activityagainst M. tuberculosis50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more68.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- RiociguatExisting use: Hypertension, Idiopathic and/or familial pulmonary arterial hypertension, Pulmonary arterial hypertension and 1 more68.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TrichlormethiazideExisting use: Cardiovascular disease67.9% AI-predicted activityagainst M. tuberculosis1 registered study
- Promazine HydrochlorideExisting use: Psychosis67.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- VandetanibExisting use: Cancer, Medullary thyroid gland carcinoma, Neoplasm and 4 more67.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydroflumethiazideExisting use: Cardiovascular disease67.7% AI-predicted activityagainst M. tuberculosis1 registered study
Registered studies
A registration describes a study; it does not establish a positive result.
An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors
NCT06915727 · start 2025-04-15
Registered record
- Registry ID
- NCT06915727
- Conditions
- Childhood Malignant Solid Neoplasm; Childhood Malignant Thoracic Neoplasm; Malignant Abdominal Neoplasm; Malignant Neck Neoplasm; Malignant Pelvic Neoplasm; Metastatic Childhood Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection; Near Infrared Imaging; Pafolacianine Sodium; Surgical Procedure
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2025-04-15
- Completion
- 2027-05-01
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChildhood Malignant Solid Neoplasm; Childhood Malignant Thoracic Neoplasm; Malignant Abdominal Neoplasm; Malignant Neck Neoplasm +2 moreInterventionBiospecimen Collection; Near Infrared Imaging; Pafolacianine Sodium; Surgical ProcedurePhasePhase 3Registry statusRecruiting